On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823

HIV Infection

COMPLETED PHASE2

Pre-Exposure Prophylaxis in YMSM

NCT01033942

HIV

COMPLETED PHASE2

Pre-exposure Option for Reducing HIV in the UK.(PROUD)

NCT02065986

HIV

COMPLETED PHASE4

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

NCT01769456

HIV Infection

COMPLETED PHASE2

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NCT02495779

Human Immunodeficiency Virus

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial has been taken place in two phases in order to ensure the general feasibility of the study:

* a first enrollment phase for at least 300 participants to ensure the possibility for recruitment in France and Canada and to validate the tools put into place as part of the trial to enroll and follow participants
* a second phase of 1600 additional participants. This extension phase started on July 2014.

The recruitment has been suspended following the recommendations of Data Safety and Monitoring Board (DSMB): the placebo arm has been stopped and Truvada was available for all the participants of the trial since November 2014. The initial protocol was amended and 361 participants were enrolled in the open-label phase. Sub-studies were proposed to the participants:

* Sub-study on the outcome of participants receiving sofosbuvir/ledipasvir treatment for recent HCV infection (protocol amendment on April 2015)
* Randomized sub-study to evaluate the efficacy of doxycycline post-exposure prophylaxis on sexually transmitted infections (protocol amendment on July 2015)
* Sub-study to evaluate Truvada adherence with Medication Event Monitoring System (MEMS) (protocol amendment on December 2015)
* Sub-study on drugs use and the impact on sexual behavior and Truvada adherence (protocol amendment on December 2015).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Truvada

associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)

Group Type ACTIVE_COMPARATOR

Truvada

Intervention Type DRUG

2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later

Placebo of Truvada

associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Truvada

2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later

Intervention Type DRUG

Placebo

2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tenofovir disoproxil and emtricitabine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old
* Male (or transgender) having sex with men
* Not infected with HIV-1 or HIV-2
* Elevated risk of HIV contamination : anal sexual relations with at least 2 different sexual partners within the past 6 months without the systematic use of a condom
* Satisfactory kidney function with a clearance of more than 60 mL/min (Cockcroft formula)
* Alanine aminotransferase (ALT) \< 2.5 Upper Limit of Normal (ULN),
* Neutrophil granulocytes ≥ 1 000/mm3, haemoglobin ≥ 10 g/dL, platelets ≥ 150 000/mm3
* Negative HBs antigen and negative hepatitis C virus (HCV) serology (or negative HCV PCR if positive serology)
* Agrees to be contacted personally, if possible by telephone, short message system (SMS) or e-mail
* Agrees to the constraints imposed by the trial (visits every 2 months)
* Subjects enrolled in or a beneficiary of a Social Security program (State Medical Aid or Aide médicale de l'Etat (AME) is not a Social Security program).
* Signature of the informed consent form.

Exclusion Criteria

* Subject in a stable and exclusive relationship with a person
* Systematic use of a condom during sexual relations
* Expected to go abroad for more than 3 consecutive months or move expected to a city where the study is not being conducted.
* Presence of significant glycosuria or proteinuria \> 1+ in the urine dipstick, in the absence of infection.
* Presence of significant haematuria or leukocyturia \> 2+ in the urine dipstick, in the absence of infection.
* History of chronic kidney disease, osteoporosis, osteopaenia
* History of pathological bone fracture not related to trauma
* Treatment with Interferon, Interleukin, or antiretrovirals
* Treatment that could inhibit or compete with the tubular secretion of antiretrovirals
* Treatment undergoing investigation
* Intravenous toxicomania
* Subject who is currently receiving or going to receive a potentially nephrotoxic treatment (long-term anti-inflammatory)
* Gastro-intestinal disease (or chronic nausea or vomiting) disrupting the absorption of treatments
* Positive HBs antigen
* Positive HCV serology with positive HCV PCR
* Life-threatening disease (lymphoma) or other serious disease (cardiovascular, renal, pulmonary, unstable diabetes) that could require treatment that could disrupt adherence to the treatment
* Subject potentially non-compliant.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes